Patterns of serum laboratory monitoring for safety and efficacy in patients on chronic statin therapy

Therapeutic Advances in Drug Safety

Volumn 4, Issue 1, 2013, Pages 9-17

  Lowe, Rachel N ^a   Marrs, Joel C ^b   Saseen, Joseph J ^b  

^a CALIFORNIA NORTHSTATE UNIVERSITY   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

drug therapy monitoring; dyslipidemia; hepatic transaminases; hydroxyl 3 methyl glutaryl coenzyme A reductase inhibitors; statin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; FEMALE; HUMAN; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 84875495422     PISSN: 20420986     EISSN: 20420994     Source Type: Journal    
DOI: 10.1177/2042098612474293     Document Type: Article

References (24)

1. Alford J. Saseen J. Allen R. Nair K. (2012) Persistent use of against-label statin-fibrate combinations from 2003-2009 despite United States food and drug administration dose restrictions. Pharmacotherapy 32: 623–630.
2. Bader T. (2010) The myth of statin-induced hepatotoxicity. Am J Gastroenterol 105: 978–980.
3. Baigent C. Keech A. Kearney P. Blackwell L. Buck G. Pollicino C. (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366: 1267–1278.
4. Bays H. Ose L. Fraser N. Tribble D. Quinto K. Reyes R. (2004) A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther 26: 1758–1773.
5. Bristol-Myers Squibb (2011) Pravachol (package insert). Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda (accessed 24 December 2012).
6. Centers for Medicare and Medicaid Services (2012). Clinical Laboratory Fee Schedule. Available at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/clinlab.html (accessed 26 June 2012).
7. Cholesterol Treatment Trialists– Collaborative (2012) The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380: 581–590.
8. Cohen D. Anania F. Chalasani N. (2006) An assessment of statin safety by hepatologists. Am J Cardiol 97: 77C–81C.
9. Colhoun H. Betteridge D. Durrington P. Hitman G. Neil H. Livingstone S. (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364: 685–696.
10. Downs J. Clearfield M. Weis S. Whitney E. Shapiro D. Beere P. (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279: 1615–1622.
11. FDA (2012) FDA Drug Safety Communication: Important Safety Label Changes to Cholesterol-lowering Statin Drugs. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm (accessed 24 December 2012).
12. Goldberg A. Sapre A. Liu J. Capece R. Mitchel Y. (2004) Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 79: 620–629.
13. Grundy S. Vega G. Yuan Z. Battisti W. Brady W. Palmisano J. (2005) Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol 95: 462–468.
14. Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360: 7–22.
15. McKenney J. Davidson M. Jacobson T. Guyton J. (2006) Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 97: 89C–94C.
16. Merck & Co (2010) Mevacor (package insert). Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda (accessed 24 December 2012).
17. Merck & Co (2011) Zocor (package insert). Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda (accessed 24 December 2012).
18. NCEP Adult Treatment Panel III (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106: 3143–3421.
19. Pearson T. Laurora I. Chu H. Kafonek S. (2000) The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 160: 459–467.
20. Phillips L. Branch W. Cook C. Doyle J. El-Kebbi I. Gallina D. (2001) Clinical inertia. Ann Intern Med 135: 825–834.
21. Ridker P. Danielson E. Fonseca F. Genest J. Gotto A. Kastelein J. (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359: 2195–2207.
22. Stagnitti M. (2008) Trends in statins utilization and expenditures for the U.S. civilian noninstitutionalized population, 2000 and 2005. Statistical Brief #205. May 2008. Agency for Healthcare Research and Quality, Rockville, MD.
23. Tice S. Parry D. (2001) Medications that require hepatic monitoring. Hosp Pharm 36: 456–464.
24. Waters D. Brotons C. Chiang C. Ferrieres J. Foody J. Jukema J. (2009) Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation 120: 28–34.